Hemab secures $135m in Series B funding for rare bleeding disorder treatment
pharmafile | February 21, 2023 | News story | Research and Development |
Hemab Therapeutics announced it received $135m from their oversubscribed Series B funding round. The funding will be used for their rare blood disorders programme, which involves lesser-known bleeding disorders.
A phase 1/2 trial, looking at Hemab’s lead asset HMB-001 as a treatment for Glanzmann Thrombasthenia, is currently running in the UK. HMB-001 is a bispecific antibody which binds to, stabilises and recruits factor Vlla at the site of vascular injury to help the blood clot. Preliminary data anticipated to be available by the second half of 2023.
A second drug ‒ HMB-VWF ‒ is indicated for von Willebrand Disease (VWD). Currently, it is in preclinical stages, however the company predicts entrance into the clinic by 2024.
Both studies are hoping to benefit from the Series B funding, which was led by all brand-new investors.
“Hemab is fundamentally reimagining the treatment paradigm for underserved bleeding and thrombotic disorders. This financing will allow us to progress our clinical programs for the first prophylactic treatments for Glanzmann Thrombasthenia and von Willebrand Disease, delivering functional cures for patients in need. We’re grateful for this robust syndicate of investors who support our approach of leveraging validated advanced technologies and deep insights into the biology of clotting to overcome decades of scientific stagnation,” stated Benny Sorensen, MD, PhD, CEO and president of Hemab.
“Strong investor confidence ‒ in this case, an upsized round and more than $200m in demand ‒ is a testament to the expertise of the Hemab team, their validated scientific approach, and the opportunity to bring long-overdue innovation to patients living with severe bleeding and thrombotic diseases,” said John Maraganore, PhD, chair of Hemab’s Board of Directors.
James Spargo
